J&J asks MHRA for antifungal switch
This article was originally published in The Tan Sheet
Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)
You may also be interested in...
Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
An early childhood fascination with the natural world led Cesar de la Fuente into the fields of microbiology and immunology. A PhD from the University of British Columbia – and postdoc work at Massachusetts Institute of Technology – helped him combine computer science principles with biological processes. As the leader of a machine biology group and lab at the University of Pennsylvania, de la Fuente is working to develop new antibiotics to treat deadly bacterial infections.
Missteps on convalescent plasma and the revoked authorization of hydroxychloroquine – paired with US president Trump’s cheerleading for the rapid approval of a COVID-19 vaccine – has eroded public trust in the US FDA. Can a safety and efficacy pledge from vaccine developers tamp down public skepticism?